A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma	HER2/Neu+ Uterine Serous Carcinoma	Recruiting	Phase 2	2026-06-22		NCT02491099

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Boehringer Ingelheim	158
Yale University	458

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Massachusetts General Hospital	Boston	United States	1015
University of Arizona Cancer Center	Tucson	United States	13
Yale New Haven Hospital	New Haven	United States	52

Clinical trials